Schmid John P. — SEC Form 4 filings

SEC reporting owner CIK 1478916. 28 Form 4 filings on record with FilingPulse; latest filed 2026-08-10.

Transaction summary — filings shown

Covers all 28 filings on record, filed 2024-01-05 to 2026-08-10. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
ANAPTYSBIO, INC (ANAB)Director113 legs · 20,645 sh · $1,158,45138
Design Therapeutics, Inc. (DSGN)Director42 legs · 26,965 sh · $99,7383
BlossomHill Therapeutics, Inc. (BLSM)Director11 leg · 6,000 sh · $96,000
Xeris Biopharma Holdings, Inc. (XERS)Director54 legs · 18,700 sh · $40,3151
First Tracks Biotherapeutics, Inc. (TRAX)Director418
Poseida Therapeutics, Inc. (PSTX)Director211
BridgeBio Oncology Therapeutics, Inc. (BBOT)12

Form 4 filings — Schmid John P.

FiledFormIssuerReported transactionsSource
2026-08-104BlossomHill Therapeutics, Inc. (BLSM)Purchase (P): 6,000 @ $16EDGAR
2026-06-174ANAPTYSBIO, INC (ANAB)Option exercise (M): 6,030 @ $0 · Option exercise (M): 6,030 (derivative) @ $0EDGAR
2026-06-174First Tracks Biotherapeutics, Inc. (TRAX)Option exercise (M): 6,030 @ $0 · Option exercise (M): 6,030 (derivative) @ $0EDGAR
2026-06-124/AFirst Tracks Biotherapeutics, Inc. (TRAX)Grant/award (A): 2,500 (derivative) @ $0 · Grant/award (A): 7,000 (derivative) @ $0EDGAR
2026-06-114Design Therapeutics, Inc. (DSGN)Grant/award (A): 30,000 (derivative) @ $0EDGAR
2026-05-144First Tracks Biotherapeutics, Inc. (TRAX)Grant/award (A): 15,000 (derivative) @ $0 · Grant/award (A): 42,000 (derivative) @ $0EDGAR
2026-04-224ANAPTYSBIO, INC (ANAB)Disposition to issuer (D): 15,000 (derivative) @ $0 · Grant/award (A): 15,000 (derivative) @ $0 · Disposition to issuer (D): 6,000 (derivative) @ $0 · Grant/award (A): 6,000 (derivative) @ $0 · Disposition to issuer (D): 6,000 (derivative) @ $0 · Grant/award (A): 6,000 (derivative) @ $0 · +14 moreEDGAR
2026-04-224First Tracks Biotherapeutics, Inc. (TRAX)Grant/award (A): 15,000 (derivative) @ $0 · Grant/award (A): 6,000 (derivative) @ $0 · Grant/award (A): 6,000 (derivative) @ $0 · Grant/award (A): 11,000 (derivative) @ $0 · Grant/award (A): 11,000 (derivative) @ $0 · Grant/award (A): 9,200 (derivative) @ $0 · +6 moreEDGAR
2026-04-014ANAPTYSBIO, INC (ANAB)Sale (S): 12,596 @ $55.71 · Sale (S): 7,527 @ $56.70 · Sale (S): 522 @ $57.40EDGAR
2026-01-084ANAPTYSBIO, INC (ANAB)Grant/award (A): 5,500 (derivative) @ $0 · Grant/award (A): 4,000 (derivative) @ $0EDGAR
2025-12-234ANAPTYSBIO, INC (ANAB)Other (J): 11,068 @ $51EDGAR
2025-08-114BridgeBio Oncology Therapeutics, Inc. (BBOT)Option exercise (M): 30,000 · Option exercise (M): 30,000 (derivative) @ $0EDGAR
2025-06-174ANAPTYSBIO, INC (ANAB)Option exercise (M): 6,030 @ $0 · Option exercise (M): 6,030 (derivative) @ $0EDGAR
2025-06-124Design Therapeutics, Inc. (DSGN)Grant/award (A): 19,000 (derivative) @ $0EDGAR
2025-03-274ANAPTYSBIO, INC (ANAB)Other (J): 11,068 @ $18.18EDGAR
2025-01-154ANAPTYSBIO, INC (ANAB)Option exercise (M): 21,692 @ $4.55 · Option exercise (M): 20,645 @ $8.54 · Option exercise (M): 21,692 (derivative) @ $0 · Option exercise (M): 20,645 (derivative) @ $0EDGAR
2025-01-084Poseida Therapeutics, Inc. (PSTX)Code (U): 58,950 · Disposition to issuer (D): 32,076 (derivative) @ $0 · Disposition to issuer (D): 16,038 (derivative) @ $0 · Disposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 25,833 (derivative) @ $0 · +3 moreEDGAR
2025-01-074ANAPTYSBIO, INC (ANAB)Grant/award (A): 16,510 (derivative) @ $0 · Grant/award (A): 6,030 (derivative) @ $0EDGAR
2024-08-134Xeris Biopharma Holdings, Inc. (XERS)Purchase (P): 4,515 @ $2.25EDGAR
2024-08-124Xeris Biopharma Holdings, Inc. (XERS)Purchase (P): 4,285 @ $2.37EDGAR
2024-06-184ANAPTYSBIO, INC (ANAB)Option exercise (M): 3,900 @ $0 · Option exercise (M): 3,900 (derivative) @ $0EDGAR
2024-06-184Poseida Therapeutics, Inc. (PSTX)Grant/award (A): 19,650 @ $0 · Grant/award (A): 27,350 (derivative) @ $0EDGAR
2024-06-174Design Therapeutics, Inc. (DSGN)Grant/award (A): 19,000 (derivative) @ $0EDGAR
2024-06-054Xeris Biopharma Holdings, Inc. (XERS)Grant/award (A): 50,000 @ $0EDGAR
2024-05-104Xeris Biopharma Holdings, Inc. (XERS)Purchase (P): 5,400 @ $1.91EDGAR
2024-03-254Design Therapeutics, Inc. (DSGN)Purchase (P): 9,156 @ $3.62 · Purchase (P): 17,809 @ $3.74EDGAR
2024-03-144Xeris Biopharma Holdings, Inc. (XERS)Purchase (P): 4,500 @ $2.16EDGAR
2024-01-054ANAPTYSBIO, INC (ANAB)Grant/award (A): 16,510 (derivative) @ $0 · Grant/award (A): 6,030 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-04 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1478916 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →